SGLT2 Inhibitors and how they work beyond the glucosuric effect. State of the art
No hay miniatura disponible
Fecha
2024
Autores
Aristizábal‑Colorado, David
Ocampo‑Posada, Martín
Rivera‑Martínez, Wilfredo Antonio
Corredor‑Rengifo, David
Rico‑Fontalvo, Jorge
Gómez‑Mesa, Juan Esteban
Duque‑Ossman, John Jairo
Abreu‑Lomba, Alin
Título de la revista
ISSN de la revista
Título del volumen
Editor
Springer
Resumen
Type 2 diabetes mellitus (T2DM) is associated with a heightened risk of cardiovascular and renal complications. While
glycemic control remains essential, newer therapeutic options, such as SGLT2 inhibitors, offer additional benefits beyond
glucose reduction. This review delves into the mechanisms underlying the cardio-renal protective effects of SGLT2 inhibitors.
By inducing relative hypoglycemia, these agents promote ketogenesis, optimize myocardial energy metabolism, and
reduce lipotoxicity. Additionally, SGLT2 inhibitors exert renoprotective actions by enhancing renal perfusion, attenuating
inflammation, and improving iron metabolism. These pleiotropic effects, including modulation of blood pressure, reduction
of uric acid, and improved endothelial function, collectively contribute to the cardiovascular and renal benefits observed
with SGLT2 inhibitor therapy. This review will provide clinicians with essential knowledge, understanding, and a clear
recollection of this pharmacological group’s mechanism of action.
Descripción
Palabras clave
Citación
Aristizábal-Colorado, D., Ocampo-Posada, M., Rivera-Martínez, W.A. et al. SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art. Am J Cardiovasc Drugs (2024). https://doi.org/10.1007/s40256-024-00673-1
